India, April 27 -- Sun Pharmaceutical Industries and US-based Organon & Co. have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $ 14.00 per share in an all‑cash transaction with an enterprise valuation of $11.75 billion.

Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women's health, the company's portfolio includes more than 70 products across Women's Health and General Medicines, which includes biosimilars, commercialised across 140 countries, wi...